EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe – a multicenter study

Daniel David, Dinah Zur, Amit Biran, Sharon Braudo, Koby Brosh, Elad Moisseiev, Shiri Shulman, Yoreh Barak, Rita Ehrlich, Shalev Fried, Alon Peled, David Hauser und 4 weitere

Graefe's Archive for Clinical and Experimental Ophthalmology · 2026-11 · 264 (11) · 3689-3696

DOI: 10.1007/s00417-026-07285-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, online erschienen am 29.05.2026. Verfasst von Daniel David und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Sheba Medical Center, Faculty of Medical and Health Sciences, Goldschleger Eye Institute, Tel Aviv University, Tel Aviv,…. Hauptthemen laut MEDLINE: Endophthalmitis, Eye Infections, Bacterial, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate endophthalmitis rates following intravitreal injection of aflibercept, comparing between vial preparation and prefilled syringe use.

Methods

We retrospectively collected data from ten ophthalmology departments in Israel. The number of intravitreal anti-VEGF injections administered in years 2022 and 2023 was recorded. Endophthalmitis rates in 2022 (vial use) and in 2023 (prefilled syringe use) were compared. Clinical details of endophthalmitis cases were reviewed.

Results

In 2022, out of 119,904 intravitreal injections, 31,991 (27%) were aflibercept injections prepared from vials. In 2023, out of 128,306 intravitreal injections, 35,589 (28%) were aflibercept injections from prefilled syringes. Endophthalmitis rates were similar between vial preparation (1:1991) and prefilled syringe (1:2372) ( p = 0.63). Notably, aflibercept injections exhibited significantly higher endophthalmitis rates compared to bevacizumab and ranibizumab combined, in both years (1:1999 vs. 1:5494 in 2022, and 1:2373 vs. 1:7132 in 2023, respectively; p < 0.01 for both).

Conclusion

Despite the transit to prefilled aflibercept syringes, endophthalmitis rates following aflibercept injection did not decrease. Post-injection endophthalmitis rates were significantly higher with aflibercept compared to bevacizumab and ranibizumab, with both vial and prefilled syringe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndophthalmitisEye Infections, BacterialReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsSyringesFemaleHumansMaleAngiogenesis InhibitorsFollow-Up StudiesIncidenceIntravitreal InjectionsRetrospective StudiesVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

AfliberceptAnti-vascular endothelial growth factor (VEGF)EndophthalmitisIntra-vitreal injectionPre-filled syringe

Substanzen

afliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Sheba Medical Center, Faculty of Medical and Health Sciences, Goldschleger Eye Institute, Tel Aviv University, Tel Aviv, Israel. danieldavid3@gmail.com.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. danieldavid3@gmail.com.
  • Division of Ophthalmology, Tel Aviv Medical Center, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Ophthalmology, Shaare Zedek Medical Center, Faculty of medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Ophthalmology, Faculty of Medical and Health Sciences, Meir Medical Center, Tel Aviv University, Tel Aviv, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

David, D., Zur, D., Biran, A., Braudo, S., Brosh, K., Moisseiev, E., Shulman, S., Barak, Y., Ehrlich, R., Fried, S., Peled, A., Hauser, D., Jaouni, T., Pras, E., Hayat, H., & Katz, G. (2026). Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe – a multicenter study. Graefe's Archive for Clinical and Experimental Ophthalmology, 264(11), 3689-3696. https://doi.org/10.1007/s00417-026-07285-2

Vancouver

David D, Zur D, Biran A, Braudo S, Brosh K, Moisseiev E, et al. Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe – a multicenter study. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026;264(11):3689-3696. doi:10.1007/s00417-026-07285-2

BibTeX
@article{David2026,
  author = {David, Daniel and Zur, Dinah and Biran, Amit and Braudo, Sharon and Brosh, Koby and Moisseiev, Elad and Shulman, Shiri and Barak, Yoreh and Ehrlich, Rita and Fried, Shalev and Peled, Alon and Hauser, David and Jaouni, Tareq and Pras, Eran and Hayat, Hagay and Katz, Gabriel},
  title = {Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe – a multicenter study},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2026},
  volume = {264},
  number = {11},
  pages = {3689--3696},
  doi = {10.1007/s00417-026-07285-2}
}
Kostenlos starten →